NasdaqGS:INCYBiotechs
The Bull Case For Incyte (INCY) Could Change Following FDA Approval Of Once-Daily Jakafi XR
In early May 2026, Incyte received U.S. FDA approval for Jakafi XR, a once-daily extended-release ruxolitinib tablet for multiple hematologic and graft-versus-host disease indications, after bioequivalence and safety were established against the existing twice-daily formulation.
This approval, alongside materially higher first-quarter 2026 revenue of US$1.27 billion and net income of US$303.33 million versus a year earlier, underscores how incremental product enhancements and portfolio...